Caris Life Sciences (CAI) said Thursday it has launched Caris ChromoSeq, a whole genome sequencing and whole transcriptome assay designed to support the clinical genomic evaluation of myeloid malignancies.

Caris ChromoSeq can replace the multiple tests needed to identify clinically relevant mutations, structural variants in myeloid malignancie, thus, complementing a clinician's overall clinical and pathological evaluation, the company said.